Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $14.56 Consensus Price Target from Analysts

Inozyme Pharma, Inc. (NASDAQ:INZY) has been assigned an average rating of “Buy” from the nine analysts that are covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $14.56.

A number of research firms recently commented on INZY. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Inozyme Pharma in a research note on Tuesday, March 11th. Raymond James dropped their price objective on shares of Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating on the stock in a report on Wednesday, March 12th. Wells Fargo & Company reduced their target price on Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. Wedbush reissued an “outperform” rating and issued a $7.00 price objective (down from $12.00) on shares of Inozyme Pharma in a report on Monday, March 10th. Finally, Piper Sandler reduced their price objective on Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th.

Inozyme Pharma Stock Performance

Shares of Inozyme Pharma stock opened at $0.92 on Wednesday. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. The stock’s fifty day moving average price is $1.22 and its 200-day moving average price is $2.93. The firm has a market cap of $59.10 million, a P/E ratio of -0.59 and a beta of 1.32. Inozyme Pharma has a 12 month low of $0.91 and a 12 month high of $7.80.

Institutional Trading of Inozyme Pharma

Several institutional investors have recently added to or reduced their stakes in the stock. Harvest Investment Services LLC purchased a new position in shares of Inozyme Pharma during the fourth quarter worth $31,000. Graham Capital Management L.P. purchased a new position in Inozyme Pharma during the 4th quarter valued at about $33,000. China Universal Asset Management Co. Ltd. acquired a new position in Inozyme Pharma in the 4th quarter valued at about $38,000. D. E. Shaw & Co. Inc. purchased a new stake in Inozyme Pharma during the fourth quarter worth about $49,000. Finally, ProShare Advisors LLC purchased a new position in shares of Inozyme Pharma in the fourth quarter valued at approximately $49,000. Institutional investors and hedge funds own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.